Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9574 first-in-human monotherapy and combination study in advanced solid malignancies
2023-504984-17-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of palacaparib in Nonhematologic neoplasms, glioma, breast cancer and 5 more (5 arms), sponsored by AstraZeneca. Planned start Oct 2022; status: authorised.
02
Drugs
palacaparib
03
Conditions
Nonhematologic neoplasmsgliomabreast cancerendometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on 2023-504984-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504984-17-00.